2011 Fiscal Year Final Research Report
Development of novel medication strategy and drug efficacy on monocyte lineage cells of a JAK3 inhibitor in rheumatoid arthritis patients
| Project/Area Number |
21591275
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
膠原病・アレルギー・感染症内科学
|
|---|
| Research Institution | University of Occupational and Environmental Health, Japan |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TANAKA Yoshiya 産業医科大学, 医学部, 教授 (30248562)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Keywords | リウマチ学 / 樹状細胞 / サイトカイン / 骨代謝 / 滑膜線維芽細胞 / Jak3 |
|---|
| Research Abstract |
In order to evaluate the effect of a Jak3-inhibitor CP690, 550(CP) on rheumatoid arthritis patients, we have focused on monocyte lineage cells, a progenitor for osteoclasts essential for bone resorption and dendritic cells(DCs) that functions as a start point of immune reaction. Differentiation of osteoclasts and DCs were not affected by the addition of CP. Bone resorption of osteoclasts was not affected by CP as well. Although, expression of co-stimulatory molecules on DCs were suppressed and co-culture of lymphocytes resulted in suppressed lymphocyte proliferation and IFN-g production.
|
Research Products
(42 results)
